53963-43-2 Usage
Description
GINSENOSIDEF1 is a bioactive metabolite derived from the ginsenoside component of Panax ginseng, a genus of plants commonly known as ginseng. It is a dammarane-type triterpenoid saponin, characterized by the presence of hydroxy groups at specific positions and a double bond at the 24-25 position. GINSENOSIDEF1 has gained attention for its potential applications in various fields, particularly in the realm of medicine.
Uses
Used in Pharmaceutical Industry:
GINSENOSIDEF1 is used as an active pharmaceutical ingredient for its anti-cancer therapeutic properties. It has the ability to inhibit human cytochrome P450 enzymes, which are involved in the metabolism of various drugs and toxins. This inhibition can potentially enhance the effectiveness of certain cancer treatments and reduce the risk of drug interactions.
Used in Liver Protection:
GINSENOSIDEF1 is also used as a hepatoprotective agent, providing protective effects on the liver. This is particularly important in the context of cancer treatment, as many chemotherapy drugs can cause liver damage. By offering liver protection, GINSENOSIDEF1 may help to mitigate some of the side effects associated with cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 53963-43-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,9,6 and 3 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 53963-43:
(7*5)+(6*3)+(5*9)+(4*6)+(3*3)+(2*4)+(1*3)=142
142 % 10 = 2
So 53963-43-2 is a valid CAS Registry Number.
InChI:InChI=1/C36H62O9/c1-19(2)10-9-12-36(8,45-31-28(43)27(42)26(41)24(18-37)44-31)35(7)15-14-34(6)21-16-22(38)29-32(3,4)25(40)11-13-33(29,5)20(21)17-23(39)30(34)35/h10,20-31,37-43H,9,11-18H2,1-8H3/t20?,21?,22-,23+,24-,25?,26-,27-,28-,29?,30-,31+,33-,34-,35+,36-/m1/s1
53963-43-2Relevant articles and documents
Characterization of metabolism and in vitro permeability study of notoginsenoside R1 from radix notoginseng
Ruan, Jian-Qing,Leong, Weng-Im,Yan, Ru,Wang, Yi-Tao
experimental part, p. 5770 - 5776 (2011/08/05)
As a main and characteristic constituent in Radix notoginseng, the fate of notoginsenoside R1 (NGR1) in human is largely unknown. The present study investigated, for the first time, NGR1 metabolism by human intestinal bacteria and liver subcellular fractions, and permeability properties of NGR1 and resultant metabolites on a Caco-2 model. Samples were qualitatively analyzed using HPLC-MS/MS and quantitatively determined using HPLC-UV. When incubated with pooled human intestinal bacteria anaerobically, NGR1 showed biphasic elimination: an insignificant decrease in the first 8 h followed by a rapid elimination during 8-48 h. Four metabolites, three unambiguously identified as ginsenosides Rg1, F1 and 20(S)-protopanaxatriol formed via stepwise deglycosylation, and one tentatively assigned as a dehydrogenated protopanaxatriol with transformation occurring at the tetracyclic triterpenoid skeleton, were produced sequentially. Rg1 and F1 were formed transiently at low apparent velocities, while 20(S)-protopanaxatriol was the major metabolite with a formation rate close to the rate of NGR1 elimination and a low elimination rate. NGR1 remained intact in human liver S9 or microsomes over 1 h. Transport study of NGR1 and its metabolites revealed an ascending permeability order with stepwise deglycosylation. Taken together, the results revealed a determinant role of intestinal bacteria in the overall disposition and potential bioactivity of NGR1 in human.